News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Poulton Jeffrey V.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/23/2023 |
3
| Poulton Jeffrey V. (Director) has filed a Form 3 on CervoMed Inc. |
08/07/2023 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 4,518 shares
@ $0 Granted 3,109 shares
@ $0 Sold 658 shares
@ $184.7, valued at
$121.5k
Sold 1,593 shares
@ $185.54, valued at
$295.6k
Sold 944 shares
@ $186.39, valued at
$176k
Sold 86 shares
@ $187.37, valued at
$16.1k
Sold 15 shares
@ $188.4, valued at
$2.8k
Sold 164 shares
@ $189.31, valued at
$31k
|
|
06/15/2023 |
4
| Poulton Jeffrey V. (Director) has filed a Form 4 on Homology Medicines, Inc.
Txns:
| Granted 23,000 options to buy
@ $1.03, valued at
$23.7k
|
|
04/28/2023 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 3,277 shares
@ $0 Sold 81 shares
@ $193.18, valued at
$15.6k
Sold 372 shares
@ $193.93, valued at
$72.1k
Sold 414 shares
@ $194.94, valued at
$80.7k
Sold 42 shares
@ $195.65, valued at
$8.2k
Sold 68 shares
@ $197.08, valued at
$13.4k
|
|
03/01/2023 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 5,724 restricted stock units
@ $0 Granted 11,850 options to buy
@ $190.01, valued at
$2.3M
|
|
08/05/2022 |
4
| Poulton Jeffrey V. (EVP, CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 4,518 shares
@ $0 Granted 3,698 shares
@ $0 Granted 3,109 shares
@ $0 Paid exercise price by delivering 4,573 shares
@ $189.76, valued at
$867.8k
Paid exercise price by delivering 162 shares
@ $209.83, valued at
$34k
Paid exercise price by delivering 146 shares
@ $209.88, valued at
$30.6k
Paid exercise price by delivering 173 shares
@ $210.5, valued at
$36.4k
|
|
06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/22/2021 |
4
| Poulton Jeffrey V. (Director) has filed a Form 4 on Homology Medicines, Inc.
Txns:
| Granted 18,000 options to buy
@ $7.26, valued at
$130.7k
|
|
04/21/2021 |
4
| Poulton Jeffrey V. (CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 4,518 shares
@ $0 Paid exercise price by delivering 1,333 shares
@ $131.75, valued at
$175.6k
Paid exercise price by delivering 50 shares
@ $134.49, valued at
$6.7k
Acquired 38 shares
@ $0 |
|
02/26/2021 |
4
| Poulton Jeffrey V. (CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Granted 23,200 options to buy
@ $151.59, valued at
$3.5M
|
|
07/21/2020 |
4
| Poulton Jeffrey V. (Director) has filed a Form 4 on Homology Medicines, Inc.
Txns:
| Granted 36,000 options to buy
@ $16.48, valued at
$593.3k
|
|
07/21/2020 |
3
| Poulton Jeffrey V. (Director) has filed a Form 3 on Homology Medicines, Inc. |
02/28/2020 |
4
| Poulton Jeffrey V. (CFO) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.
Txns:
| Acquired 19 shares
@ $0 Granted 24,554 options to buy
@ $118.05, valued at
$2.9M
|
|
08/13/2019 |
3
| Poulton Jeffrey V. (CFO) has filed a Form 3 on ALNYLAM PHARMACEUTICALS, INC. |
|
|